NuVasive Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
NuVasive Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, NuVasive's Price has gone down from $35.49 to $0.00 – a 100.00% drop. In the next year, analysts are expecting an increase in Fair Value, predicting it will reach $0.00 – an increase of 100.00%. The NuVasive forecast is for Fair Value to reach $0.00 or grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$151.18 | Buy/Sell | $174.55 | 12.45% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$106.29 | Buy/Sell | $118.92 | 19.01% |
| SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$328.12 | Buy/Sell | $353.16 | 12.31% |
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$80.89 | Buy/Sell | $92.47 | 18.06% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.34 | Buy/Sell | $44.86 | 11.55% |
NuVasive Revenue Forecast for 2023 - 2025 - 2030
In the last two years, NuVasive's Revenue has increased by 14.41%, going from $1.05B to $1.20B. In the next year, 0 analysts estimate that NuVasive's Revenue will decrease by 6.08%, reaching $1.13B. According to professional forecasts, in 2030, NuVasive's Revenue will decrease by 5.87%, reaching $1.13B.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SN. Stock Forecast | Smith & Nephew | Outperform |
18
|
£9.77 | Buy/Sell | £16.09 | 67.96% |
| GMED Stock Forecast | Globus Medical | Outperform |
16
|
$50.43 | Buy/Sell | $64.58 | 18.98% |
| HAE Stock Forecast | Haemonetics | Outperform |
16
|
$92.13 | Buy/Sell | $70.17 | 13.97% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ITGR Stock Forecast | Integer Holdings | Outperform |
16
|
$109.78 | Buy/Sell | $95.00 | 18.42% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.08 | Buy/Sell | $42.58 | 16.82% |
| ATEC Stock Forecast | Alphatec Holdings | Buy |
7
|
$12.97 | Buy/Sell | $21.85 | 77.33% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| OFIX Stock Forecast | Orthofix Medical | Hold |
10
|
$13.03 | Buy/Sell | $18.00 | 15.12% |
| ANIK Stock Forecast | Anika Therapeutics | Outperform |
10
|
$26.49 | Buy/Sell | $27.33 | 20.80% |
| XTNT Stock Forecast | Xtant Medical Holdings | Buy |
0
|
$0.86 | Buy/Sell | $1.93 | 124.42% |
NuVasive EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, NuVasive's EBITDA has grown, increasing from $180.73M to $218.17M – a growth of 20.72%. 0 analysts predict NuVasive's EBITDA will decrease by 9.66% in the next year, reaching $197.09M. By 2030, professionals predict that NuVasive's EBITDA will decrease by 9.18%, to $198.14M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ELUT Stock Forecast | Elutia | Buy |
2
|
$3.94 | Buy/Sell | $0.00 | 26.90% |
| ATE Stock Forecast | Antibe Therapeutics | Hold |
-10
|
C$0.30 | Buy/Sell | C$1.69 | 566.67% |
| OZSC Stock Forecast | Ozop Energy Solutions | - |
0
|
$0.00 | Buy/Sell | $0.00 | 0.00% |
NuVasive EBIT Forecast for 2023 - 2025 - 2030
In the last two years, NuVasive's EBIT has grown by 66.25%, from $50.19M to $83.44M. For the following year, the 0 analysts predict that NuVasive's EBIT will drop by 25.20%, reaching $62.42M. In 2030, the professionals' prediction is that NUVA's EBIT will decrease by 21.80%, reaching $65.25M.
NuVasive EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, NuVasive's EPS has gone down from $1.23 to $0.00 – a 100.00% drop. In the next year, analysts are expecting an increase in EPS, predicting it will reach $0.00 – an increase of 100.00%. The NuVasive forecast is for EPS to reach $0.00 or grow by 100.00%.
.jpg)